Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Inclusion Criteria

• Histological confirmation of non-small cell lung cancer
• Patients who have been treated in the past with stereotactic radiosurgery, stereotactic radiotherapy, GliaSite or surgical resection will be allowed to enroll in this study
• A diagnostic contrast-enhanced MRI or CT scan must be performed, demonstrating brain metastases
• Age 18-70
• Patients must have KPS >/= 70
• Patients cannot be treated on any other treatment related protocols within 30 days prior to study entry or during participation in the study
• No uncontrolled or symptomatic major medical illnesses or psychiatric impairments, such as Alzheimer's or schizophrenia
• Screening Clinical Laboratory Values: ANC >1500/ul, Platelets >80,000/ul, baseline AST and/or ALT within normal limits (within 30 days of starting protocol treatment)
• All women of childbearing potential (A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months [i.e., who has had menses at any time in the preceding 24 consecutive months]) and male participants must practice effective contraception (abstinence, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.
• Continued from #10: All women of child-bearing potential must have a negative serum pregnancy test and practice birth control while on study.
• Patients must provide verbal and written informed consent to participate in the study.

Exclusion Criteria

• Prior cranial radiation therapy, other than stereotactic radiosurgery, Stereotactic Radiotherapy or GliaSite.
• Patients with known Acquired Immune Deficiency (AIDS), as regimens with tyrosine kinase inhibitors may pose a safety risk related to excess toxicity or interference with anti-viral effectiveness
• Women who are pregnant or lactating, due to possible adverse effects on the developing fetus or infant due to study drug
• Patients with active connective tissue disorders, such as lupus or scleroderma